Hemab Therapeutics Holdings, a Phase 3-ready biotech developing blood coagulation disorder treatments, raised the proposed deal size for its upcoming IPO on Thursday.
The Cambridge, MA-based company now plans to raise $255 million by offering 15 million shares at a price range of $16 to $18. The company had previously filed to offer 11.8 million shares at the same range. At the midpoint, Hemab Therapeutics Holdings will raise 27% more in proceeds than previously anticipated.
Hemab is a clinical-stage biotechnology company developing antibody-based therapies for inherited bleeding and coagulation disorders. Its lead candidate, sutacimig (HMB-001), finished Phase 2 and is ready for Phase 3 for Glanzmann thrombasthenia and Phase 2 for Factor VII deficiency, while HMB-002 is in Phase 1/2 for Von Willebrand Disease. The company’s programs are focused on prophylactic subcutaneous treatments for rare disorders with limited existing options, and it is also advancing additional preclinical candidates in coagulation-related diseases.
Hemab Therapeutics Holdings was founded in 2020. It plans to list on the Nasdaq under the symbol COAG. Goldman Sachs, Jefferies, and Evercore ISI are the joint bookrunners on the deal. It is expected to price the week of April 27, 2026.
